This is an ambitious proposal to use placebo arm data from more than 30 antipsychotic drug clinical trials to better understand symptoms after therapy discontinuation. I was confused by one thing: how will the Ki values, defined as specific receptor affinities, be estimated? My understanding is that PK information is needed to calculate Ki values, which I do not expect to be available within the RCT data, but perhaps I am misunderstanding. Please clarify.
Approve